Skip to main content

Advertisement

SpringerLink
Log in

Effects of Hedan Tablet (荷丹片) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the effects of Hedan Tablet (荷丹片) on serum lipid profile, proprotein convertase subtilisin/kexin type 9 (PSCK9) and high-density lipoprotein (HDL) subfractions in patients with hyperlipidemia.

Methods

Thirty-seven patients with hyperlipidemia were randomized to treatment with Hedan Tablet 4.38 g/day as Hedan group (18 cases) or placebo (19 cases) as control group for 8 weeks. The lipid profile, PCSK9 and HDL subfractions were determined at day 0 and week 8 in both groups respectively.

Results

Hedan treatment for 8 weeks mildly decreased serum low-density lipoprotein cholesterol (LDL-C) levels, while no changes were found in total cholesterol (TC), triglycerides (TG) and PCSK9 concentrations. Furthermore, Hedan treatment increased the concentration of large high-density lipoprotein cholesterol (HDL-C) and the percentage of large HDL subfraction, while decreased the concentration of small HDL-C and the percentage of small HDL subfraction without changing serum HDL-C levels in patients with hyperlipidemia.

Conclusion

Hedan treatment of 4.38 g per day for 8 weeks could confer a favorable effects on serum LDL-C concentration as well as HDL subfractions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Satoh H, Nishino T, Tomita K, Tsutsui H. Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men—results from a 10-year cohort study. Circ J 2006;70:227–231.

    Article  CAS  PubMed  Google Scholar 

  2. Mahalle N, Garg MK, Naik SS, Kulkarni MV. Study of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven coronary artery disease. Indian J Endocrinol Metab 2014;18:48–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dou XB, Wo XD, Fan CL. Progress of research in treatment of hyperlipidemia by monomer or compound recipe of Chinese herbal medicine. Chin J Integr Med 2008;14:71–75.

    Article  CAS  PubMed  Google Scholar 

  4. Soltani R, Hakimi M, Asgary S, Ghanadian SM, Keshvari M, Sarrafzadegan N. Evaluation of the effects of Vaccinium arctostaphylos L. fruit extract on serum lipids and hs-CRP levels and oxidative stress in adult patients with hyperlipidemia: a randomized, double-blind, placebocontrolled clinical trial. Evid Based Complement Alternat Med 2014;2014:217451.

    PubMed  PubMed Central  Google Scholar 

  5. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11:367–383.

    Article  CAS  PubMed  Google Scholar 

  6. Jia YJ, Zhang Y, Liu J, Guo YL, Xu RX, Li JJ. Short-and long-term effects of Xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels. Chin J Integr Med 2014 Jul 4. [Epub ahead of print]

    Google Scholar 

  7. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50:S172–S177.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009;13:19–28.

    Article  CAS  PubMed  Google Scholar 

  9. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010;51:2714–2721.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Awan Z, Seidah NG, Mac Fadyen JG, Benjannet S, Chasman DI, Ridker PM, et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012;58:183–189.

    Article  CAS  PubMed  Google Scholar 

  11. Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013;2:e000028.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008;49:394–398.

    Article  CAS  PubMed  Google Scholar 

  13. Wen C, Xu H. The new strategy for modulating dyslipidemia: consideration from updated understanding on high-density lipoprotein. Chin J Integr Med 2011;17:467–470.

    Article  CAS  PubMed  Google Scholar 

  14. Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011;124:555–562.

    Article  CAS  PubMed  Google Scholar 

  15. Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol 2012;59:2058–2064.

    Article  CAS  PubMed  Google Scholar 

  16. Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279–1291.

    Article  Google Scholar 

  17. Superko HR, Pendyala L, Williams PT, Momary KM, King SB, Garrett BC. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol 2012;6:496–523.

    Article  PubMed  Google Scholar 

  18. Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57:392–410.

    Article  CAS  PubMed  Google Scholar 

  19. Barylski M, Toth PP, Nikolic D, Banach M, Rizzo M, Montalto G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab 2014;28:453–461.

    Article  CAS  PubMed  Google Scholar 

  20. Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDLtargeted therapies: progress, failures and future. Nat Rev Drug Discov 2014;13:445–464.

    Article  CAS  PubMed  Google Scholar 

  21. Wan FC, Huang DZ. Hypolipidemic effect of Hedan Tablet. Chin J Exp Tradit Med Form (Chin) 1996;2:19–21.

    Google Scholar 

  22. Hu YY. Evaluation of efficacy and safety for Hedan treatment in patients with dyslipidemia. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2013;11:1135–1136.

    Google Scholar 

  23. Goliasch G, Oravec S, Blessberger H, Dostal E, Hoke M, Wojta J, et al. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (</= 40 years of age). Eur J Clin Invest 2012;42:631–636.

    Article  CAS  PubMed  Google Scholar 

  24. Christogiannis LG, Kostapanos MS, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens 2013;27:44–50.

    Article  CAS  PubMed  Google Scholar 

  25. Tian Q, Gu SY, Liu YF. Effect of Hedan on lipid profile in patients with hypetlipidemia. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2013;11:1290–1291.

    Google Scholar 

  26. Fu XL, Zhan QL, Meng FJ, Ying YH, Tian XY, Yang YB, et al. Effects of Hedan Tablet on lipid pfrofile and vasscular endothelial function in elder hyperlipidemic patients. Modern J Integr Tradit Chin West Med (Chin) 2013;22:4015–4016.

    Google Scholar 

  27. Chen YL. The intervention effect of Hedan Tablet combined with atorvastatin on cytokine in carotid atherosclerosis. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2013;10:808–810.

    Google Scholar 

  28. Wang L, Zheng GN. Comparation of the effects between Hedan and atorvastatin on lipid profile in patients with hyperlipidemia. Chin J Ethnomed Ethnopharm (Chin) 2012;24:61–62.

    CAS  Google Scholar 

  29. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11:367–383.

    Article  CAS  PubMed  Google Scholar 

  30. Urban D, Pöss J, Böhm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 2013;62:1401–1408.

    Article  CAS  PubMed  Google Scholar 

  31. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010;5:2714–2721.

    Article  Google Scholar 

  32. Barylski M, Toth PP, Nikolic D, Banach M, Rizzo M, Montalto G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab 2014;28:453–461.

    Article  CAS  PubMed  Google Scholar 

  33. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991;84:129–139.

    CAS  PubMed  Google Scholar 

  34. Fendler W, Rizzo M, Borowiec M, Malachowska B, Antosik K, Szadkowska A, et al. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol 2014;51:625–632.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Xu RX, Guo YL, Li XL, Li S, Li JJ. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype. Clin Exp Pharmacol Physiol 2014;41:475–481.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China

    Rui-xia Xu  (徐瑞霞), Na-qiong Wu  (吴娜琼), Sha Li  (李 莎), Yan Zhang  (张 彦), Xiao-lin Li  (李小林), Yuan-lin Guo  (郭远林), Cheng-gang Zhu  (朱成刚), Geng Liu  (刘 庚), Qian Dong  (董 倩) & Jian-jun Li  (李建军)

Authors
  1. Rui-xia Xu  (徐瑞霞)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Na-qiong Wu  (吴娜琼)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sha Li  (李 莎)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Zhang  (张 彦)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-lin Li  (李小林)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuan-lin Guo  (郭远林)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cheng-gang Zhu  (朱成刚)
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Geng Liu  (刘 庚)
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Qian Dong  (董 倩)
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jian-jun Li  (李建军)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-jun Li  (李建军).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, Rx., Wu, Nq., Li, S. et al. Effects of Hedan Tablet (荷丹片) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study. Chin. J. Integr. Med. 22, 660–665 (2016). https://doi.org/10.1007/s11655-015-2140-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-015-2140-3

Keywords

Search

Navigation